Clark N.W., Holbrook I.B., McClure J,
è ñîàâò. Osteoclast inhibition by
pamidronate in metastatic prostate cancer: a preliminary study // Br. J. Cancer. —
1991. — V. 63. — P. 420 423.
Cocconi G., De Lissi V., Boni C., Mori P,. Malacarne P., Amadori D., Giobannelli E.
Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced
breast cancer // Cancer 1983. — V. 4 — P. 581 588.
Cohen J.A., Keller J.H., Marie A. Abate.
Therapy reviews. Managment of breast can
cer // Clinical. Pharmacy. — 1982 V. 1. — P. 515 526.
Coleman R.E., Rubens R.D.
Breast cancer and bone metastases // Cancer Treat.
Rev. — 1985. — V. 12. — P. 251 270.
Coleman R.E., Rubens R.D.
The clinical course of bone metastases from breast can
cer // Brit. J. Cancer. — 1987. — V. 55. — P. 61 66.
Coleman R.E., Rubens R.D., Fogelman J.
A reappraised of the baseline bone scan in
breast cancer // J. Nucl. Med. — 1988. — V. 29. — P. 1045 1049.
Coleman R.E., Rubens R.D., Fogelman J.
The bone scan flare following systemic
therapy for bone metastases // J. Nucl. Med. — 1988. — V. 29. — P.1354 1359.
Coleman R.E., Whitaker K.D., Moss D.W., Mashiter G., Fogelman J., Rubens R.D.
Biochemical monitoring predicts response in bone metastases to treatment // Br. J.
Cancer. — 1988. — V. 58. — P. 205 210.
Coleman R.E.
Assessment of respone to treatment // In: Bone metastases. Eds.
Rubens R.D., Fogelman J. — London: Springer. — 1991. — P.99 117.
Coleman R.E., Purohit O.P., Vinholes J.J.
The future of bisphosphonates in cancer //
Acta Oncol. — 1996. — V. 35 (Suppl. 5). — P. 23 29.
Coleman R.E., Purohit O.P., Vinholes J.J., Zekri J.
High dose pamidronate: clinical
and biochemical effects in metastatic bone disease // Cancer. — 1997. — V. 80 (Suppl. 8). —
P. 1686 1690.
Coleman R.E., Houston S., Purohit O.P., Rubens R.D., Kandra A., Ford J.
A ran
domised phase II study of oral pamidronate for the treatment of bone metastases from
breast cancer // Eur. J. Cancer. — 1998. — V. 34(6). — P. 820 824.
Coleman R.E.
How can we improve the treatment of bone metastases further? //
Curr. Opin. Oncol. — 1998. — V. 10 (Suppl. 1). — P. 7 13.
Coleman R.E., Smith P., Rubens R.D.
Clinical course and prognostic factors follow
ing bone recurrence from breast cancer // Br. J. Cancer. — 1998. — V. 77(2). — P. 336
340.
Coleman R.E., Houston S., Purohit O.P., Rubens R.D., Kandra A., Ford J.
A ran
domised phase II study of oral pamidronate for the treatment of bone metastases from
breast cancer // Eur. J. Cancer. — 1998. — V. 34 (6) — P. 820 824.
Coleman R.E., Purohit O.P., Black C., Vinholes J.J., Schlosser K., Huss H., Quinn
K.J., Kanis J.
Double blind, randomised, placebo controlled, dose finding study of oral
ibandronate in patients with metastatic bone disease // Ann. Oncol. — 1999. — V. 10(3). —
P. 311 316.
Compell D., Banks A., Cats L.
The value of preliminary bone scaning in staging and
assesting the prognosis of breast cancer // Brit. J. Surg. — 1976. — V. 63. — P. 811 816.
Constans J.P., de DiVitiis E., Donzelli R.
è ñîàâò. Spinal metastases with neurologi
cal manifestation. Review of 600 cases // J. Neurosurg. — 1983. — V. 59. — P. 111 118.
Conte P.F., Giannessi P.G., Latreille J., Mauriac L., Koliren L., Calabresi F., Ford
J.M.
Delayed progression of bone metastases with pamidronate therapy in breast cancer
221
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
